Daniel R. Day advises clients on a combination of evidence collection strategy, clinical evidence translation, and market insight related to medical products.
Specifically, Dr. Day focuses on aspects of quality measurement as they relate to the translation of clinical guidelines for use in pay-for-reporting and pay-for-performance programs. In this role he assists clients in shaping tactical plans and in the execution of quality measure assessment, feasibility, and development.
Prior to joining Avalere, he served as a member of the Scientific Advisory Board and program coordinator with Terosin Group, Inc., and as a visiting scientist at the University of California at Santa Barbara.
Daniel has a PhD in pharmacology, an MA in molecular cellular biology, and a BS in biological sciences from the University of California at Santa Barbara.